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DETERMINATION OF A DIFFERENTIAL PROTEIN PROFILE IN THE
SYNOVIAL FLUID OF PATIENTS WITH RHEUMATOID ARTHRITIS AND
OSTEOARTHRITIS
J. Mateos, P. Ferna´ndez-Puente, V. Calamia, L. Lourido, C. Ferna´ndez-
Lo´pez, N. Oreiro, C. Ruiz-Romero, F.J. Blanco. Osteoarticular and Aging Res.
Lab., Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A
Corun˜a, Spain
Purpose: Early detection of a biomarker – or a panel of biomarkers –
related to the arthritic processes would be of capital importance not
only for the prediction of the pathology, but also for its handling, the
developing of trials of treatment and, of course, a deeper understanding
of the disease. Our aim for this study was to identify proteins
differentially abundant in the Synovial Fluid from patients suffering
from Rheumatoid Arthritis (RA) or Osteoarthritis (OA) using mass
spectrometry.
Methods: 20 individual samples for each condition were pooled in two
groups with the aim of reducing the contribution of individual extreme
values. Since SF presents a similar dynamic range than serum in terms
of protein concentration, we decided to immuno-deplete the samples to
enrich them in the low-abundant protein fraction. After that, the pooled
samples were subjected to protein size fractioning and in-gel digestion,
followed by Reverse Phase peptide separation in a nano-LC system and
peptide identiﬁcation by MALDI-TOF/TOF. Relative quantitative analysis
and validation of selected proteins was done by Spectral Counting and
Western blot techniques, respectively.
Results: Our results show that in RA there is a relative more abundance
of proteins related to immﬂamation and immune response, such as
major matrix metalloproteinases, MMP-1 and MMP-3, as well as MRP-8,
Calgranulin-A and Plastin-2, all known markers of inﬂammation and
immune response. On the contrary, we found in OA that proteins involved
in the formation and remodelling of the extracelular matrix [ECM],
between them Fibronectin, Kininogen-1, Cartilage Acidic Protein 1
and Cartilage Oligomeric Matrix Protein are relatively more abundant,
suggesting a possible role in the pathological process. Validation by
Western blot of two differentially accumulated proteins, MMP-1 and
Fibronectin, in individual SF samples supports the mass spectrometry
data.
Conclusions: Since SF is in direct contact with the affected tissues –
cartilage, synovial membrane and bone – it results an excellent source
for biomarker discovery. All together, our data show that LC-MALDI-
TOF/TOF is a technique suitable to face the current need of discovering
early indicators in the OA process, since we have demonstrated that
comparative quantitation of two different pathologies affecting the joint,
RA vs OA, yields substantially different protein proﬁles. Also, the relative
abundance of ECM proteins in SF samples from OA patients strongly
supports that enhanced ECM production and turnover by activated
metalloproteases is a central hallmark in the pathogenic process in OA
leading to progressive erosion of structural integrity of the joint and
eventual loss of functional performance.
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TWO NOVEL SUPERSENSITIVE BIOCHEMICAL MARKERS OF
INFLAMMATION, MATRIX METALLOPROTEINASE AND CATHEPSIN
GENERATED FRAGMENTS OF C-REACTIVE PROTEIN
H. Skjot-Arkil1, A-C. Bay-Jensen1, G. Schett2, D.J. Leeming1, M.A. Karsdal1.
1Nordic BioSci. A/S, Herlev, Denmark; 2Univ. of Erlangen-Nuremberg,
Erlangen, Germany
Purpose: Joint degenerative diseases (JDD) are widely affected by
inﬂammation joints. Current markers of inﬂammation, such as C-reactive
protein (CRP), are reﬂecting the production of an acute phase reactant
rather than tissue speciﬁc inﬂammation.
The use of CRP as marker for JDD has not provided the sought accuracy
and speciﬁcity. We hypothesized that local enzymatic activity (e.g. MMPs
and Cathepsins) in the affected tissue, which is associated with extensive
tissue turnover, may cleave the CRP produced in the liver and produce
a more tissue speciﬁc CRP. These cleavage products of CRP may provide
additional information on the systemic inﬂammation compated to that
provided by traditional full length CRP. We investigated whether these
CRP degradation products would provide additional diagnostic value
by measuring two newly developed MMP and cathepsin mediated CRP
fragments in patients with JDD.
Methods: CRP fragments were identiﬁed by mass-spectrometry. Two
fragments were selected as antigens for antibody development, followed
by ELISA development. One assay exclusively identiﬁed a matrix
metalloproteinase (MMP) generated fragment, CRP-MMP, whereas the
other assay identiﬁed a cathepsin generated fragment, CRP-CAT. The
ELISA was characterized and the technical performance was tested and
recorded. Full-length CRP, CRP-MMP and CRP-CAT were measured in
serum samples from 40 patients and 40 sex and age-matched controls.
Results: The accuracy and precision was acceptable with low inter- and
intra-assay variation (<10%), as well as dilution recovery. Full-length CRP
was not elevated in the patients compared to controls, whereas CRP-
MMP was elevated by 25% (p < 0.001) and CRP-CAT by 50% (p < 0.0001).
The AUC of the ROC of CRP-CAT was the highest with 77%.
Conclusions: MMP and cathepsin degraded CRP provided more
discriminative diagnostic potential compared to that of full-length CRP
in this current study. These data suggest that different pools of CRP
may provide insight into the inﬂammation processes in JDD. Further
studies are needed to investigate wether these novel fragments have
more prognostic power compared that of full length CRP.
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CORRELATION OF KNEE CARTILAGE THICKNESS CHANGE AT 1 YEAR
WITH CLINICAL OUTCOME CHANGES AT 1 AND 3 YEARS: DATA FROM
THE OSTEOARTHRITIS INITIATIVE
R. Buck1, M. Nevitt2, W. Wirth3,4, F. Eckstein3,4. 1StatAnswers Consulting
LLC, Minnetonka, MN, USA; 2Univ. of California and OA Initiative
Coordinating Ctr., San Francisco, CA, USA; 3Paracelsus Med. Univ., Salzburg,
Austria; 4Chondrometrics, Ainring, Germany
Purpose: An important characteristic of any biomarker is that it
be associated with clinical outcomes and ideally be able to predict
future outcomes. Change in knee cartilage thickness is an important
characteristic of osteoarthritis and is believed to impact clinical outcomes
such as pain assessments which are key to disease management. Hence
small short-term changes in knee cartilage thickness may predict changes
in future clinical outcomes. The OAI study provides an opportunity
to examine the relationship between short (1 year) changes in knee
cartilage thickness and concurrent (1 year) or future (3 years) changes
in clinical outcomes.
Methods: Measurements of change in mean subregional cartilage
thickness (DThCtAB) over 12 months were available from coronal FLASH
MR images for one knee of 795 OAI subjects, 185 men and 242 women
from the Progression cohort and 135 men and 233 women from the
Incidence cohort. Subjects were restricted to those that underwent some
change in clinical outcomes. The Progression cohort was split to consider
signal (osteophytes and pain present) and non-signal knees (either
osteophytes or pain not present) separately. See Table for sample sizes.
Baseline and follow-up scans were read in pairs with readers blinded
to visit. Change in ThCtAB was measured in 16 femorotibial subregions
[2]. Linear models considering all subregion DThCtAB were constructed
to predict change in clinical outcomes over 3 years (DOutcome). Clinical
outcomes examined were WOMAC (Total, Pain, Stiffness, Disability) or
KOOS (Pain, Symptom) individual knee scores. Ordered values (OV)
of DThCtAB were also considered as predictors [1]. Ordered values
were considered for medial and lateral subregions separately and
combined (All). Coefﬁcient of determination (%), R2, was used to measure
association between multivariate Predictors and DOutcomes.
Table: The coefﬁcients of determination (%: min, mean, max) across
clinical outcomes for different cohorts
Cohort Interval ThCtAB med+lat OV All OV
Incidence 1 Year (0.0, 1.0, 2.9) (1.3, 3.8, 6.3) (2.3, 7.2, 11.2)
3 Year (0.0, 0.6, 1.8) (1.5, 5.1, 13) (3.0, 5.0, 8.1)
Progression 1 Year (2.9, 4.7, 8.1) (3.1, 5.1, 7.4) (1.9, 3.5, 4.9)
3 Year (3.0, 4.6, 7.0) (4.3, 5.5, 6.3) (1.6, 4.1, 7.4)
Signal knee 1 Year (4.0, 6.0, 9.3) (2.2, 5.0, 7.1) (4.5, 8.1, 12.1)
3 Year (5.5, 8.2, 12.3) (4.9, 7.1, 8.8) (5.0, 7.2, 10.4)
Non-signal 1 Year (4.5, 14.3, 23.1) (20.1, 22.8, 28.7) (9.2, 18.3, 29.4)
3 Year (3.0, 6.5, 10.5) (12.6, 19.9, 24.9) (8.8, 14.8, 28.7)
Results: R2 was relatively consistent across clinical outcomes. R2 was
typically low (<0.07) when predicting DOutcome using all subjects,
Incidence or Progression cohorts. R2 increased when signal and non-
signal knees of Progression cohort are considered separately, particularly
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for non-signal knee with OV as predictors (R2 > 0.09). Over 80% of the
correlations between DThCtAB and DOutcome examined had p-values
<0.05 at 1 and 3 Years, with most (13 of 22 at 1 Year and 12 of 20
at 3 Years) non-signiﬁcant correlations observed with Incidence cohort.
Correlation between DThCtAB at 1 Year and DOutcome at 3 Years was
signiﬁcant (p < 0.05) after adjusting for DOutcome at 1 Year for nearly all
outcomes.
Conclusions: DThCtAB at 1 year helps predict DOutcome at 3 Years even
after adjusting for DOutcome at 1 Year. The use of ordered values (OV)
as predictors produced larger R2 than use of subregion DThCtAB Results.
Non-signal knees of Progression cohort had larger R2 than signal knees.
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ENHANCED COMP CATABOLISM DETECTED IN SERUM OF PATIENTS
WITH ARTHRITIS AND ANIMAL MODELS THROUGH A NOVEL
CAPTURE ELISA
Y. Lai1, Y. Zhang1, Q. Tian1, H. Song1, M.T. Mucignat2, R. Perris2,
M. Attur1, J.D. Greenberg1, S.B. Abramson1, P.E. Di Cesare3, C-J. Liu1.
1New York Univ., New York, NY, USA; 2Univ. of Parma, Parma, Italy; 3UC
Davis Med. Ctr., Sacramento, CA, USA
Purpose: There are several commercial enzyme-linked immunosorbent
assay (ELISA) kits available for measuring COMP levels in human serum;
however, these reagents lack speciﬁcity for degraded COMP fragments,
which may hinder the usefulness of the test for the clinical monitoring
of arthritis. The goal of this study is to develop a COMP fragment ELISA
to measure levels of proteolytic COMP fragments in serum, and to
determine whether detection of COMP degradative fragments will be
a more sensitive biomarker of arthritis.
Methods:We generated a panel of monoclonal antibodies (mAbs) against
COMP fragments and then characterized the mAbs domain speciﬁcity.
We developed a novel capture ELISA for detecting COMP fragments and
utilized this new test to measure the amount of degradative COMP
fragments in patients with osteoarthritis (OA) and rheumatoid arthritis
(RA). This test was also developed as an assay for the possible monitoring
of the effects of interventions. This new test was then used to monitor
OA progression in surgically induced OA animal models as well as the
alteration in COMP fragment levels in response to biological treatments
in collagen-induced arthritis (CIA) and TNF transgenic animal models.
Results: A panel of murine mAbs against recombinant COMP fragments
was generated and one of these clones, 2127F 5B6, was identiﬁed
as a mAb preferentially recognizing the COMP C-terminal degradative
fragments. A novel COMP fragment ELISA was then developed using
mAb 2127F 5 as a detection antibody. Compared with a commercial
COMP ELISA kit that detected no signiﬁcant difference in total COMP
levels between symptomatic knee OA (SKOA) and non-OA control groups,
a signiﬁcant increase of the COMP fragments was noted in the serum
of SKOA patients assayed by this newly established COMP ELISA. In
addition, serum COMP fragment levels were well correlated with the
Kellgren-Lawrence grade score in OA patients and the progression of
surgically induced OA in murine models. Furthermore, the levels of COMP
fragments in the serum of RA patients, mice with CIA, and TNF transgenic
mice were signiﬁcantly higher when compared with their corresponding
controls. Interestingly, treatments with TNFa inhibitors and methotrexate
led to a signiﬁcant decrease of serum COMP fragments in RA patients.
Additionally, administration of Atsttrin, a progranulin-derived engineered
protein that binds to TNFR and has potent anti-inﬂammatory activity
(Tang, et al, Science, 2011 Apr 22; 332(6028):478–484), also resulted in a
signiﬁcant reduction in serum COMP fragments in several inﬂammatory
arthritis mice models.
Conclusions: Using recombinant COMP fragments we have generated a
series of mAbs that recognize different domains on the COMP protein.
One of these antibodies that bind to the C-terminal portion of the
molecule was then used to develop a novel sandwich ELISA capable of
reproducibly measuring the levels of COMP fragments (COMP catabolism)
in the body ﬂuids of both arthritic patients and murine arthritis models.
In addition, this new test provides a valuable means to utilize serum
COMP fragments as a biomarker for monitoring the effects of therapeutic
interventions on arthritis.
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FEASIBILITY OF LARGE-SCALE ASSESSMENT OF BIOCHEMICAL
MARKERS FOR OSTEOARTHRITIS: AN ANALYSIS IN CHECK
W.E. van Spil1, N.W. Jansen1, J.W. Bijlsma1, M. Reijman2, J. DeGroot3,
P.M. Welsing1, F.P. Lafeber1. 1Univ. Med. Ctr. Utrecht, Utrecht, Netherlands;
2Erasmus Med. Ctr., Rotterdam, Netherlands; 3TNO Quality of Life, Zeist,
Netherlands
Purpose: Osteoarthritis (OA) is currently regarded as a complex joint
disease; multiple articular and peri-articular structures being involved,
probably in a variable sequence and dominance between individuals.
However, current literature on biochemical OA markers mainly concerns
small-scale assessments of limited numbers of biochemical markers and
is thereby discordant with this view. Instead, large-scale assessment
of multiple biochemical markers is preferable. Large-scale assessment
might be regarded unfeasible because of complex logistics, high ﬁnancial
burden, and the increased risk of inducing technical variability. This
publication analyzes the feasibility of such a large-scale assessment of a
wide spectrum of biochemical markers.
Methods: Eleven biochemical markers (CTX-II, COMP, CS846, PIIANP, C1,2C,
CTX-I, NTX-I, OC, PINP, PIIINP, HA) were assessed in urine or serum
samples of 1002 participants (Cohort Hip & Cohort Knee; CHECK) by
means of ELISA and RIA in an academic laboratory and commercially-
independent setting. The assessment was necessarily performed by
multiple technicians, in multiple assay plates, and during multiple
days. Therefore, speciﬁc attention to minimizing technically-induced
variability was vital. In addition to evaluation of several technical aspects,
reliability of single instead of multiple assessments per sample was
evaluated. A standard sample was repeatedly included in all assay
plates throughout the assessment period to quantify technically-induced
variability (3 levels: within plates, within all plates on a day, in all
plates throughout the assessment period) and evaluate adjustment for
between-plate variability.
Results: The additional variation that was introduced by single instead of
multiple sample assessments was limited and considered acceptable in the
context of logistics, scarcity of samples, and costs (triplicate assessment
in a subset of samples showed high correlation between biochemical
marker concentrations in the ﬁrst sample and the mean concentration
in triplets; rs 0.841–0.996, P 0.000). Of the 11,000 assessments that
were performed, 27 and 19 assessments showed concentrations that
were below or above the standard curve, respectively. Re-assessment in
adjusted dilutions induced (unpredictable) non-linear dilution effects
and was considered inappropriate. Instead, artiﬁcial concentrations
(0.8*minimum, 1.2*maximum concentration) were used. Technically-
induced variability increased stepwise between the 3 levels (intra-plate <
within day < total), but not statistically signiﬁcantly. Correction for
technically-induced between-plate variability on the basis of the standard
sample assessment that was performed in all plates decreased the CV% of
median biochemical marker concentrations between plates (mean ratio
after/before adjustment 0.96; SD 0.3). Three of the 11 biomarkers showed
unanticipated results. One could be re-assessed successfully, the other 2
remained unsolved, despite thorough analyses in consultancy with the
manufacturer.
Conclusions: Large-scale biochemical marker assessments pose speciﬁc
challenges. However, this study shows that large-scale assessment is
feasible for the vast majority of the studied biochemical markers.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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BIOMARKERS OF KNEE OSTEOARTHRITIS: CORRELATION WITH
OUTERBRIDGE CLASSIFICATION
J.M. Humphries1, C.J. Wilson2, D. Morgan3, G. Mercer2, J.S. Kuliwaba1,
N.L. Fazzalari1. 1SA Pathology, Adelaide, Australia; 2Repatriation Gen. Hosp.,
Daw Park, Australia; 3Repatriation Gen. Hsopital, Daw Park, Australia
Purpose: To determine if an association exists between circulating
concentrations of serum cartilage oligomeric matrix protein (COMP)
and fatty acids, and degree of osteoarthritic degradation of the medial
and lateral condyles of the tibial plateau graded according to the
Outerbridge Classiﬁcation, in patients undergoing total knee replacement
(TKR) surgery. Identiﬁcation of an easily accessible biomarker can aid in
determination of progressive osteoarthritis and in drug development.
Methods: Sera was collected from 113 individuals presenting for TKR,
representing both male (n =51) and female (n = 62) patients with an
